Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
Can Exact Sciences (EXAS) Keep the Earnings Streak Alive This Quarter?
by Zacks Equity Research
Exact Sciences (EXAS) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)
by Zacks Equity Research
Exact Sciences Corporation (EXAS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?
by Zacks Equity Research
ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.
Why Exact Sciences (EXAS) Might Surprise This Earnings Season
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
New Strong Buy Stocks for July 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Exact Sciences (EXAS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
Exact Sciences (EXAS) Shows Strength: Stock Gains 11.7%
by Zacks Equity Research
Exact Sciences Corp. (EXAS) shares jumped almost 12% in the last trading session.
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
by Zacks Equity Research
Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.
Geron (GERN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.
Can Fitbit (FIT) Stock Surprise Investors Post Q4 Earnings?
by Zacks Equity Research
Fitbit Inc. (FIT) is set to report fourth-quarter 2016 results on Feb 22. Last quarter, the company posted a positive earnings surprise of 18.18%.
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.
What's in Store for ImmunoGen (IMGN) this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
5 Great Biotech Stocks to Buy Now
by Swarup Gupta
Biotechs have stabilized and still offer the potential to deliver substantial returns.
Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.
Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.